Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trial
peer reviewedBACKGROUND: Postmenopausal osteoporosis is a serious, chronic condition, for which nitr...
Use of ibandronate in the prevention of skeletal events in metastatic breast cance
Charles A Inderjeeth,1,2 Paul Glendenning,2,3 Shoba Ratnagobal,1 Diren Che Inderjeeth,1 Chandni Ondh...
Background/Aim: Severe bone pain is experienced by 60–80% of patients with metastatic bone disease, ...
AbstractBackground/AimSevere bone pain is experienced by 60–80% of patients with metastatic bone dis...
This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with place...
Background: This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate...
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast canc...
PubMed ID: 22868504Background: The aim of this study was to determine the efficacy and safety of loa...
Background: We report the first results of a randomized trial assessing a new oral aminobisphosphona...
Ibandronate is a potent bisphosphonate which has been most thoroughly assessed in benign bone diseas...
Metastatic bone disease puts an enormous burden on patients and health care resources. Disruption of...
Purpose<p></p> This phase II trial evaluated the efficacy and safety of loading-dose I....
Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidi...
Introduction:Approximately 80% of non-small cell lung cancer (NSCLC) patients with bone metastases h...
peer reviewedBACKGROUND: Postmenopausal osteoporosis is a serious, chronic condition, for which nitr...
Use of ibandronate in the prevention of skeletal events in metastatic breast cance
Charles A Inderjeeth,1,2 Paul Glendenning,2,3 Shoba Ratnagobal,1 Diren Che Inderjeeth,1 Chandni Ondh...
Background/Aim: Severe bone pain is experienced by 60–80% of patients with metastatic bone disease, ...
AbstractBackground/AimSevere bone pain is experienced by 60–80% of patients with metastatic bone dis...
This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with place...
Background: This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate...
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast canc...
PubMed ID: 22868504Background: The aim of this study was to determine the efficacy and safety of loa...
Background: We report the first results of a randomized trial assessing a new oral aminobisphosphona...
Ibandronate is a potent bisphosphonate which has been most thoroughly assessed in benign bone diseas...
Metastatic bone disease puts an enormous burden on patients and health care resources. Disruption of...
Purpose<p></p> This phase II trial evaluated the efficacy and safety of loading-dose I....
Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidi...
Introduction:Approximately 80% of non-small cell lung cancer (NSCLC) patients with bone metastases h...
peer reviewedBACKGROUND: Postmenopausal osteoporosis is a serious, chronic condition, for which nitr...
Use of ibandronate in the prevention of skeletal events in metastatic breast cance
Charles A Inderjeeth,1,2 Paul Glendenning,2,3 Shoba Ratnagobal,1 Diren Che Inderjeeth,1 Chandni Ondh...